Oral agent with bioavailability of 80-90%.
Protein binding is greater than 99%.
Metabolism is hepatic with a half-life of 8 to 12 hours.
Excretion is renal.
A non-steroidal anti-inflammatory drug (NSAID).
Brand name Dolobid.
Available in 250 mg and 500 mg tablets.
Acts by inhibiting the production of prostaglandins, hormones involved in inflammation and pain.
Also has an antipyretic effect.
The drug stabilizes transthyretin protein, and can be given to selective patients with ATTR cardiomyopathy, without advanced kidney disease, and who cannot receive tafamidis.
Has an onset time of 1 hour, and maximum analgesia at 2 to 3 hours.
The plasma levels of reach as steady state with repeated doses.
Has a long half-life and to reach a steady state a loading dose is usually used.
Primarily used to treat symptoms of arthritis, and for acute pain following oral surgery.
Effectiveness similar to other NSAIDs, but the duration of action is twelve hours or more.
After oral surgery can maintain analgesia until the patient is asleep that night.
Used for mild to moderate pain such as with osteoarthritis, rheumatoid arthritis, injury to tendons and inflammatory states.
Like all NSAIDS, associated with increased risk of stomach ulcers with long-term use.
Elderly patients are at greater risk for serious GI events, including bleeding, ulceration, and stomach or intestine perforation.
Patients may experience abdominal pain, cramps, constipation, diarrhea, increased gas, nausea, vomiting, and dyspepsia, irregular heart beat, possible increased risk of thrombotic events, MI, and stroke, tinnitus, drowsiness, dizziness, headache, insomnia, fatigue, nervousness, extremity edema, rash, and ecchymoses.